{"nctId":"NCT00145327","briefTitle":"Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)","startDateStruct":{"date":"2005-05"},"conditions":["Osteoporosis"],"count":2456,"armGroups":[{"label":"Zoledronic Acid 6","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic Acid"]},{"label":"Zoledronic Acid 3 Placebo 3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Placebo 3 Zoledronic Acid 3","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic Acid"]}],"interventions":[{"name":"Zoledronic Acid","otherNames":["Reclast, Aclasta"]},{"name":"Placebo","otherNames":["Reclast, Aclasta"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have received 3 infusions in the HORIZON-Pivotal Fracture (PFT) Study.\n\nExclusion Criteria:\n\n* Poor kidney, eye, or liver health\n* Use of certain therapies for osteoporosis in the HORIZON-PFT study (other than the study medication)\n* Abnormal calcium levels in the blood\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"68 Years","maximumAge":"90 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change in Bone Mineral Density (BMD) of Femoral Neck at Year 6 Relative to Year 3","description":"The primary efficacy variable was the percentage change in BMD of the femoral neck as measured by dual x-ray absorptiometry (DXA) at Year 6 relative to Year 3. It was derived as 100 \\*(femoral neck BMD at Year 6 - femoral neck BMD at Year 3) / (femoral neck BMD at Year 3).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.557","spread":"0.2154"},{"groupId":"OG001","value":"-0.493","spread":"0.2249"},{"groupId":"OG002","value":"3.337","spread":"0.2329"}]}]}]},{"type":"SECONDARY","title":"Bone Resorption and Formation Biochemical Markers at Year 4.5: P1NP","description":"The amount of serum n-terminal propeptide of type I collagen (P1NP) as determined by the central laboratory.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.842","spread":"0.4325"},{"groupId":"OG001","value":"29.677","spread":"0.6977"},{"groupId":"OG002","value":"17.256","spread":"0.3743"}]}]}]},{"type":"SECONDARY","title":"Bone Resorption and Formation Biochemical Markers at Year 6: P1NP","description":"The amount of serum P1NP as determined by the central laboratory","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.356","spread":"0.6340"},{"groupId":"OG001","value":"30.344","spread":"0.6050"},{"groupId":"OG002","value":"25.926","spread":"0.7765"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in BMD of Lumbar Spine at Year 4.5 Relative to Year 3","description":"The percentage change in BMD as measured by DXA at Year 4.5 relative to Year 3. It was derived as 100 \\* (BMD at Year 4.5 - BMD at Year 3)/(BMD at Year 3).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.618","spread":"0.384"},{"groupId":"OG001","value":"1.196","spread":"0.3510"},{"groupId":"OG002","value":"6.551","spread":"0.3035"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in BMD of Lumbar Spine at Year 6 Relative to Year 3","description":"The percentage change in BMD as measured by DXA at Year 6 relative to Year 3. It was derived as 100 \\* (BMD at Year 6 - BMD at Year 3)/(BMD at Year 3).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.473","spread":"0.4653"},{"groupId":"OG001","value":"1.606","spread":"0.4550"},{"groupId":"OG002","value":"8.875","spread":"0.5398"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in BMD of Distal Radius at Year 4.5 Relative to Year 3","description":"The percentage change in BMD as measured by DXA at Year 4.5 relative to Year 3. It was derived as 100 \\* (BMD at Year 4.5 - BMD at Year 3)/(BMD at Year 3).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.378","spread":"0.3615"},{"groupId":"OG001","value":"-0.924","spread":"0.3158"},{"groupId":"OG002","value":"0.386","spread":"0.3071"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in BMD of Distal Radius at Year 6 Relative to Year 3","description":"The percentage change in BMD as measured by DXA at Year 6 relative to Year 3. It was derived as 100 \\* (BMD at Year 6 - BMD at Year 3)/(BMD at Year 3).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.178","spread":"0.3661"},{"groupId":"OG001","value":"-0.567","spread":"0.4025"},{"groupId":"OG002","value":"0.299","spread":"0.3473"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in BMD of Femoral Neck, Total Hip and Trochanter at Year 4.5 Relative to Year 3","description":"The percentage change in BMD as measured by DXA at 4.5 relative to Year 3. It was derived as 100 \\* (BMD at Year 4.5 - BMD at Year 3)/(BMD at Year 3).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.738","spread":"0.1874"},{"groupId":"OG001","value":"0.210","spread":"0.2058"},{"groupId":"OG002","value":"2.697","spread":"0.1516"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.479","spread":"0.1337"},{"groupId":"OG001","value":"-0.070","spread":"0.1354"},{"groupId":"OG002","value":"3.228","spread":"0.1244"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.813","spread":"0.1919"},{"groupId":"OG001","value":"0.041","spread":"0.1936"},{"groupId":"OG002","value":"4.611","spread":"0.2050"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in BMD of Femoral Neck, Total Hip and Trochanter at Year 6 Relative to Year 3","description":"The percentage change in BMD as measured by DXA at Year 6 relative to Year 3. It was derived as 100 \\* (BMD at Year 6 - BMD at Year 3)/(BMD at Year 3).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.577","spread":"0.2154"},{"groupId":"OG001","value":"-0.493","spread":"0.2249"},{"groupId":"OG002","value":"3.337","spread":"0.2329"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.083","spread":"0.1647"},{"groupId":"OG001","value":"-1.151","spread":"0.1817"},{"groupId":"OG002","value":"3.815","spread":"0.1877"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.628","spread":"0.2275"},{"groupId":"OG001","value":"-0.903","spread":"0.2462"},{"groupId":"OG002","value":"6.072","spread":"0.2894"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With New and New/Worsening Morphometric Vertebral Fractures","description":"Lateral vertebral x-rays were performed at the final core study visit and at Year 6 and read by a central expert reader at a central imaging laboratory to assess for new or new/worsening morphometric vertebral fracture. The percentage of patients with new morphometric vertebral fractures (observed for the first time) and patients with either new or worsening morphometric vertebral fractures was calculated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"6.2","spread":null},{"groupId":"OG002","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"7.0","spread":null},{"groupId":"OG002","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Incidence of Clinical Fracture","description":"Clinical fracture excludes finger, toe, and facial bone fractures. Clinical vertebral fracture includes thoracic spine fracture and lumbar spine fracture. Non-vertebral fracture excludes clinical vertebral, finger, toe, and facial bone fractures.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":"8.15"},{"groupId":"OG001","value":"51","spread":"8.52"},{"groupId":"OG002","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Qualitative Bone Biopsy Parameters","description":"Unpaired transiliac crest bone biopsy was performed for histomorphometry, which was obtained after double tetracycline labeling. No data were collected for Patients who received Placebo for the first 3 years of the study (Placebo 3 Zoledronic Acid 3).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum Creatinine From Baseline to 9-11 Days Post Year 3 Infusion","description":"Serum creatinine measurements performed by a central laboratory was used to evaluate acute changes in renal function 9-11 days after study drug infusion in Z6 patients compared to Z3P3 patients and in P3Z3 patients.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":"9.364"},{"groupId":"OG001","value":"1.28","spread":"8.757"},{"groupId":"OG002","value":"0.21","spread":"12.360"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Creatinine From Baseline to 9-11 Days Post Year 4 Infusion","description":"Serum creatinine measurements performed by a central laboratory was used to evaluate acute changes in renal function 9-11 days after Year 4 study drug infusion.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.35","spread":"23.580"},{"groupId":"OG001","value":"2.23","spread":"9.891"},{"groupId":"OG002","value":"2.47","spread":"13.042"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Creatinine From Baseline to 9-11 Days Post Year 5 Infusion","description":"Serum creatinine measurements performed by a central laboratory was used to evaluate acute changes in renal function 9-11 days after Year 5 study drug infusion.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.46","spread":"21.735"},{"groupId":"OG001","value":"0.71","spread":"10.278"},{"groupId":"OG002","value":"1.04","spread":"11.882"}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Clinically Significant Laboratory Parameters","description":"Evaluate the laboratory key profile such as Calcium, Creatinine and Urea. The number of patients with clinically significant calcium, creatinine and urea were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":191,"n":613},"commonTop":["Arthralgia","Back pain","Urinary tract infection","Hypertension","Pyrexia"]}}}